JP2016147902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016147902A5 JP2016147902A5 JP2016094112A JP2016094112A JP2016147902A5 JP 2016147902 A5 JP2016147902 A5 JP 2016147902A5 JP 2016094112 A JP2016094112 A JP 2016094112A JP 2016094112 A JP2016094112 A JP 2016094112A JP 2016147902 A5 JP2016147902 A5 JP 2016147902A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- represented
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 206010012289 Dementia Diseases 0.000 claims 12
- 102000013498 tau Proteins Human genes 0.000 claims 11
- 108010026424 tau Proteins Proteins 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 238000006243 chemical reaction Methods 0.000 claims 10
- 238000010494 dissociation reaction Methods 0.000 claims 10
- 230000005593 dissociations Effects 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000003449 preventive effect Effects 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- INJRKJPEYSAMPD-UHFFFAOYSA-N aluminum;silicic acid;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O INJRKJPEYSAMPD-UHFFFAOYSA-N 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| JP2012124336 | 2012-05-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518734A Division JP5971659B2 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018051046A Division JP6620829B2 (ja) | 2012-05-31 | 2018-03-19 | 認知症治療剤又は予防剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016147902A JP2016147902A (ja) | 2016-08-18 |
| JP2016147902A5 true JP2016147902A5 (enExample) | 2016-10-06 |
| JP6406678B2 JP6406678B2 (ja) | 2018-10-17 |
Family
ID=49673425
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518734A Active JP5971659B2 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
| JP2016094112A Active JP6406678B2 (ja) | 2012-05-31 | 2016-05-09 | 認知症治療剤又は予防剤 |
| JP2018051046A Active JP6620829B2 (ja) | 2012-05-31 | 2018-03-19 | 認知症治療剤又は予防剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518734A Active JP5971659B2 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018051046A Active JP6620829B2 (ja) | 2012-05-31 | 2018-03-19 | 認知症治療剤又は予防剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (enExample) |
| EP (2) | EP2857039B1 (enExample) |
| JP (3) | JP5971659B2 (enExample) |
| KR (2) | KR102208283B1 (enExample) |
| CN (1) | CN104602708B (enExample) |
| AR (1) | AR091218A1 (enExample) |
| AU (2) | AU2013268364B2 (enExample) |
| BR (1) | BR112014029566A2 (enExample) |
| CA (1) | CA2875205C (enExample) |
| CY (1) | CY1122530T1 (enExample) |
| DK (1) | DK2857039T3 (enExample) |
| ES (2) | ES2973070T3 (enExample) |
| HR (1) | HRP20192267T1 (enExample) |
| HU (1) | HUE046919T2 (enExample) |
| IL (1) | IL235899B (enExample) |
| LT (1) | LT2857039T (enExample) |
| ME (1) | ME03587B (enExample) |
| MX (1) | MX361128B (enExample) |
| MY (1) | MY172458A (enExample) |
| NZ (1) | NZ630536A (enExample) |
| PH (1) | PH12014502669B1 (enExample) |
| PL (1) | PL2857039T3 (enExample) |
| PT (1) | PT2857039T (enExample) |
| RS (1) | RS59802B1 (enExample) |
| RU (1) | RU2657438C2 (enExample) |
| SG (2) | SG11201407878VA (enExample) |
| SI (1) | SI2857039T1 (enExample) |
| TW (2) | TWI777183B (enExample) |
| WO (1) | WO2013180238A1 (enExample) |
| ZA (1) | ZA201409186B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| JP6457263B2 (ja) * | 2011-05-20 | 2019-01-23 | オリゴメリックス インコーポレイテッド | タウプロテアーゼ組成物および使用方法 |
| HRP20192267T1 (hr) * | 2012-05-31 | 2020-03-20 | Osaka City University | Terapeutski agens ili profilaktički agens za demenciju |
| MX359555B (es) | 2012-07-03 | 2018-10-02 | Univ Washington | Anticuerpos para tau. |
| TW202136296A (zh) * | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| EP3448875A4 (en) * | 2016-04-29 | 2020-04-08 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| MX2019014174A (es) | 2017-05-30 | 2020-01-27 | Teijin Pharma Ltd | Anticuerpo anti-receptor de igf-i. |
| SG11202002575UA (en) | 2017-10-02 | 2020-04-29 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| US10829547B2 (en) | 2017-10-16 | 2020-11-10 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US11667707B2 (en) | 2018-04-06 | 2023-06-06 | Teijin Pharma Limited | SPNS2 neutralizing antibody |
| US20210230598A1 (en) * | 2018-07-04 | 2021-07-29 | National University Corporation Tokai National Higher Education And Research System | Oligonucleotides for controlling tau splicing, and uses thereof |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| JP7718270B2 (ja) | 2019-09-30 | 2025-08-05 | ニプロ株式会社 | 血液試料を検体とするタウタンパク質検出方法 |
| EP4121071A4 (en) * | 2020-03-19 | 2024-07-24 | Vascular Biosciences | PEPTIDE CAR FOR IMPROVED CORONAVIRUS SURVIVAL |
| MX2022016322A (es) * | 2020-06-25 | 2023-01-24 | Merck Sharp & Dohme Llc | Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413. |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| AU2007261584A1 (en) * | 2006-06-16 | 2007-12-27 | Envivo Pharmaceutical Inc. | Transgenic flies expressing tau and amyloid precursor fragment |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8703137B2 (en) * | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| HRP20192267T1 (hr) * | 2012-05-31 | 2020-03-20 | Osaka City University | Terapeutski agens ili profilaktički agens za demenciju |
| JOP20180014A1 (ar) * | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
-
2013
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016147902A5 (enExample) | ||
| US11261252B2 (en) | Molecules with specificity for CD79 and CD22 | |
| US20230065921A1 (en) | Antibody molecules which bind cd22 | |
| JP7166457B2 (ja) | ｃ－Ｋｉｔに対するヒト化抗体 | |
| JP6563012B2 (ja) | Ｉｌ−１５に対する抗体 | |
| US20190359713A1 (en) | Molecules with specificity for cd45 and cd79 | |
| JP2016511277A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| HRP20192267T1 (hr) | Terapeutski agens ili profilaktički agens za demenciju | |
| JP2017113028A5 (enExample) | ||
| JP2018524009A (ja) | Ｃｄ４５に結合する抗体分子 | |
| JP2014513953A5 (enExample) | ||
| JPWO2021146256A5 (enExample) | ||
| EP4259645A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| AR114436A1 (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| JPWO2020172450A5 (enExample) | ||
| EP4393946A1 (en) | Cdc platform antibody | |
| RU2022112012A (ru) | Моновалентные антитела к пропердину и фрагменты антител | |
| TW202528343A (zh) | 抗c2結合劑及其結合物 | |
| RU2019124873A (ru) | Моновалентные антитела к пропердину и фрагменты антител |